BOSTON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the presentation of preliminary data from The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma during the late-breaking session at the International Stroke Conference in Phoenix, AZ.

波士顿，2024年2月9日（环球通讯社）--全球神经血管设备技术领先者Balt，Inc.今天宣布，在亚利桑那州凤凰城举行的国际中风会议的后期休息期间，提交了Squid试验的初步数据，用于栓塞脑膜中动脉（STEM）治疗慢性硬膜下血肿。

The preliminary data demonstrates that rates of complications thus far are low and embolizing the MMA for the treatment of Chronic Subdural Hematoma (cSDH) potentially improves the success rates of both surgical and non-surgical treatments.   Co-Principal Investigator Adam Arthur, MD, MPH presented six-month follow-up data on the 310 subjects from the prospective, multi-center, multi-national randomized trial comparing patients who received embolization of the middle meningeal artery (MMA) with Squid™ Liquid Embolic as an adjunct to standard management against those who did not.

初步数据表明，迄今为止并发症的发生率很低，栓塞MMA治疗慢性硬膜下血肿（cSDH）可能会提高手术和非手术治疗的成功率。联合首席研究员Adam Arthur，MD，MPH介绍了来自前瞻性，多中心，多国随机试验的310名受试者的6个月随访数据，该试验比较了接受脑膜中动脉（MMA）栓塞的患者和Squid™液体栓塞作为标准管理的辅助手段，以对抗那些没有接受的患者。

Standard management included surgical drainage of the subdural hemorrhage for qualified patients and best medical management for patients who did not require surgery. STEM, which completed enrollment last year, is the first prospective IDE trial investigating embolization of the MMA for the treatment of chronic Sub-Dural Hematoma (cSDH).

标准管理包括合格患者的硬膜下出血手术引流和不需要手术的患者的最佳医疗管理。STEM于去年完成登记，是第一项前瞻性IDE试验，研究MMA栓塞治疗慢性硬膜下血肿（cSDH）。

Dr. Arthur, (Semmes-Murphey Neurologic and Spine Institute and University of Tennessee Health Sciences Center) further commented, “cSDH is a treatable cause of disability and death for many older patients, and this trial is a major step forward in improving treatment for these patients.” Balt CEO Pascal Girin commented, “I am very proud that we at Balt were the first company to initiate and complete enrollment in a prospective, randomized controlled trial in this important disease state that.

Arthur博士（Semmes Murphey神经病学和脊柱研究所以及田纳西大学健康科学中心）进一步评论说：“cSDH是许多老年患者残疾和死亡的可治疗原因，这项试验是改善这些患者治疗的重要一步。”Balt首席执行官Pascal Girin评论道，“我非常自豪的是，Balt是第一家在这种重要疾病状态下发起并完成前瞻性随机对照试验的公司。